Helicobacter pylori infection and eye diseases: a systematic review

Sergio Claudio Saccà, Aldo Vagge, Alessandra Pulliero, Alberto Izzotti, Sergio Claudio Saccà, Aldo Vagge, Alessandra Pulliero, Alberto Izzotti

Abstract

The connection between Helicobacter pylori (Hp) infection and eye diseases has been increasingly reported in the literature and in active research. The implication of this bacterium in chronic eye diseases, such as blepharitis, glaucoma, central serous chorioretinopathy and others, has been hypothesized. Although the mechanisms by which this association occurs are currently unknown, this review describes shared pathogenetic mechanisms in an attempt to identify a lowest common denominator between eye diseases and Hp infection. The aim of this review is to assess whether different studies could be compared and to establish whether or not Hp infection and Eye diseases share common pathogenetic aspects. In particular, it has been focused on oxidative damage as a possible link between these pathologies. Text word search in Medline from 1998 to July 2014. 152 studies were included in our review. Were taken into considerations only studies that related eye diseases more frequent and/or known. Likely oxidative stress plays a key role. All of the diseases studied seem to follow a common pattern that implicates a cellular response correlated with a sublethal dose of oxidative stress. These alterations seem to be shared by both Hp infections and ocular diseases and include the following: decline in mitochondrial function, increases in the rate of reactive oxygen species production, accumulation of mitochondrial DNA mutations, increases in the levels of oxidative damage to DNA, proteins and lipids, and decreases in the capacity to degrade oxidatively damaged proteins and other macromolecules. This cascade of events appears to repeat itself in different diseases, regardless of the identity of the affected tissue. The trabecular meshwork, conjunctiva, and retina can each show how oxidative stress may acts as a common disease effector as the Helicobacter infection spreads, supported by the increased oxidative damage and other inflammation.

Conflict of interest statement

The authors declare that there are no conflicts of interest and to be in agreement with the Declaration of Helsinki.

Figures

FIGURE 1
FIGURE 1
Anterior blepharitis of a mixed type of the upper eyelid. This shows a squamous blepharitis-hyperemic. Very evident the presence of collarettes, meibomian secretion around eyelashes (blue arrows) and telangiectasia and very hyperemic vessels of the lid margin (red arrows). Although it is unknown the role of Hp infection in this type of pathology, its eradication leads to an improvement in both subjective and objective symptoms and can, especially in the young, alleviate blepharitis.
FIGURE 2
FIGURE 2
Glaucoma in oxidative stress plays a key role in mitochondrial dysfunction occurs and consequently the endothelial cells of the trabecular meshwork are not working as they should. There is an alteration of the extracellular matrix is accompanied by the activation of several metabolic pathways that result in an alteration of gene expression, an activation of inflammation and the immune response. This determines the malfunction of the trabecular meshwork and consequently the intraocular pressure increase. All this triggers the apoptosis of retinal ganglion cells.
FIGURE 3
FIGURE 3
Sequence of the pathogenesis of Hp infection that increases the production of ROS and inflammatory cytokines, sees the recruitment of white blood cells in the presence of a decrease of antioxidant defenses leads to the alteration of gastric mucosa cells and thus of the gastric mucosal barrier.
FIGURE 4
FIGURE 4
(A) Fluoroangiography of right eye; it shows a central serous chorioretinopathy which highlights the leakage (white) in the retinal pigment epithelium with pooling of the dye in the subretinal space. (B) Indocyanine green angiography shows an area with a late iperfluorescent likeage that suggests as an etiologic factor the choroidal hyperpermeability. (C) The optical coherence tomography (OCT) allows us a qualitative and quantitative assessment of the disease. (D) OCT cross-sectional image of a fovea with central serous chorioretinopathy: The detachment of the neurosensory retina is revealed as optically empty space within the retina. The retinal pigment epithelium remains attached to the choroid and it is evident by OCT as a thin layer (arrow). The retinal layers are intact but detached in the photoreceptors are thicker and a higher reflectivity.
FIGURE 5
FIGURE 5
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma): the lymphoma cells infiltrate around reactive B-cell follicles, external to a preserved follicle mantle, in a marginal zone distribution. Marginal zone B cells have characteristics of small and medium size. The majority of patients present with stage I or II disease. The MALT lymphoma and its natural course is indolent and is slow to disseminate; recurrence may involve other extranodal sites.

References

    1. Parsonnet J, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 1999; 282:2240–2245.
    1. Leung WK, Siu KL, Kwok CK, et al. Isolation of Helicobacter pylori from vomitus in children and its implication in gastro-oral transmission. Am J Gastroenterol 1999; 94:2881–2884.
    1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002; 347:1175–1186.
    1. Mindel JS, Rosenberg EW. Is Helicobacter pylori of interest to ophthalmologists? Ophthalmology. 1997; 104:1729–1730.
    1. Saccà SC, Roszkowska AM, Izzotti A. Environmental light and endogenous antioxidants as the main determinants of non-cancer ocular diseases. Mutat Res. 2013; 752:153–171.
    1. Saccà SC, Pascotto A, Venturino GM, et al. Prevalence and treatment of Helicobacter pylori in patients with blepharitis. Invest Ophthalmol Vis Sci. 2006; 47:501–508.
    1. Kendall SN. Remission of rosacea induced by reduction of gut transit time. Clin Exp Dermatol. 2004; 29:297–299.
    1. Boni R, Rosacea acne and other diseases of the seborrheic spectrum. Schweiz Rundsch Med Prax. 2000; 89:566–570.
    1. Diaz C, O’Callaghan CJ, Khan A, Ilchyshyn A. Rosacea: a cutaneous marker of Helicobacter pylori infection? Results of a pilot study. Acta Derm Venereol. 2003; 83:282–286.
    1. Charlett A, Dobbs RJ, Dobbs SM, et al. Parkinsonism: siblings share Helicobacter pylori seropositivity and facets of syndrome. Acta Neurol Scand. 1999; 99:26–35.
    1. Gupta AK, Bluhm R, Cooper EA, Summerbell RC, Batra R Seborrheic dermatitis. Dermatol Clin. 2003; 21:401–412.
    1. Fitzpatrick JE. Common inflammatory skin diseases of the elderly. Geriatrics. 1989; 44:40–46.
    1. Utas S, Ozbakir O, Turasan A, Utas C. Helicobacter pylori eradication treatment reduces the severity of rosacea. J Am Acad Dermatol 1999; 40:433–435.
    1. Boixeda de Miquel D, Vázquez Romero M, Vázquez Sequeiros E, et al. Effect of Helicobacter pylori eradication therapy in rosacea patients. Rev Esp Enferm Dig 2006; 98:501–509.
    1. Szlachcic A, Sliwowski Z, Karczewska E, et al. Helicobacter pylori and its eradication in rosacea. J Physiol Pharmacol 1999; 50:777–786.
    1. Michel JL, Cabibel F. Frequency, severity and treatment of ocular rosacea during cutaneous rosacea. Ann Dermatol Venereol. 2003; 130:20–24.
    1. Gasbarrini A, Serricchio M, Tondi P, et al. Association of Helicobacter pylori infection with primary Raynaud phenomenon [letter]. Lancet 1996; 348:966–967.
    1. Gasbarrini A, Franceschi F. Autoimmune diseases and Helicobacter pylori infection. Biomed Pharmacother. 1999; 53:223–226.
    1. Amedei A, Bergman MP, Appelmelk BJ, et al. Molecular mimicry between Helicobacter pylori antigens and H, K-adenosine triphosphatase in human gastric autoimmunity. J Exp Med. 2003; 198:1147–1156.
    1. Gurer MA, Erel A, Erbas D, et al. The seroprevalence of Helicobacter pylori and nitric oxide in acne rosacea. Int J Dermatol 2002; 41:768–770.
    1. Gutgesell VJ, Stern GA, Hood CI. Histopathology of meibomian gland dysfunction. Am J Ophthalmol. 1982; 94:383–387.
    1. Dougherty JM, Mc Culley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis: inhibition of lipase production in Staphylococci. Invest Ophthalmol Vis Sci. 1991; 32:2970–2975.
    1. Gulbenkian A, Myers J, Fries D. Hamster flank organ hydrolase and lipase activity. J Invest Dermatol. 1980; 75:289–292.
    1. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004; 51:327–341.
    1. Cohen AF, Tiemstra JD. Diagnosis and treatment of rosacea. J Am Board Fam Pract. 2002; 15:214–217.
    1. Rebora A. The management of rosacea. Am J Clin Dermatol. 2002; 3:489–496.
    1. Song Q, Lange T, Spahr A, et al. Characteristic distribution pattern of Helicobacter pylori in dental plaque and saliva detected with nested PCR. J Med Microbiol. 2000; 49:349–353.
    1. Al-Ahmad A, Kürschner A, Weckesser S, et al. Is Helicobacter pylori resident or transient in the human oral cavity? J Med Microbiol. 2012; 61:1146–1152.
    1. Leske MC. Open-angle glaucoma: an epidemiologic overview. Ophthalmic Epidemiol 2007; 14:166–172.
    1. Ritch R. Natural Compounds: evidence for a protective role in eye disease. Can J Ophthalmol 2007; 42:425–438.
    1. Pescosolido N, Cavallotti C, Rusciano D, Nebbioso M. Trabecular meshwork in normal and pathological eyes. Ultrastruct Pathol. 2012; 36:102–107.
    1. Saccà SC, Izzotti A. Focus on molecular events in the anterior chamber leading to glaucoma. Cell Mol Life Sci. 2014; 71:2197–2218.
    1. Brenner C, Kroemer G. Apoptosis: mitochondria; the death signal integrators. Science. 2000; 289:1150–1151.
    1. Van Houten B, Woshner V, Santos JH. Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair (Amst). 2006; 5:145–152.
    1. He Y, Leung KW, Zhang YH, et al. Mitochondrial complex I defect induces ROS release and degeneration in trabecular meshwork cells of POAG patients: protection by antioxidants. Invest Ophthalmol Vis Sci. 2008; 49:1447–1458.
    1. Izzotti A, Saccà SC, Longobardi M, Cartiglia C. Mitochondrial damage in the trabecular meshwork of patients with glaucoma. Arch Ophthalmol. 2010; 128:724–730.
    1. Trounce I, Byrne E, Marzuki S. Decline in skeletal muscle mitochondrial chain function: possible factor in aging. Lancet 1989; 1:637–639.
    1. Yen TC, Chen YS, King KL, et al. Liver mitochondrial respiratory functions decline with age. Biochem Biophys Res Com 1989; 165:994–1003.
    1. Camougrand N, Rigoulet M. Aging and oxidative stress: studies of some genes involved both in aging and in response to oxidative stress. Resp Physiol 2001; 128:393–401.
    1. Tappia PS, Dent MR, Dhalla NS. Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med. 2006; 41:349–361.
    1. Lee H-C, Wei Y-H. Mitochondrial alterations, cellular response to oxidative stress and defective degradation of proteins in aging. Biogerontology 2001; 2:231–244.
    1. Ames BN, Shigenaga MK, Hagen TM Oxidants, antioxidants, and the degenerative diseases of ageing. Proc Natl Acad Sci USA 1993; 90:7915–7922.
    1. Yakes FM, van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997; 94:514–519.
    1. Parihar MS, Brewer GJ. Mitoenergetic failure in Alzheimer disease. Am J Physiol Cell Physiol. 2007; 292:C8–C23.
    1. Genova ML, Pich MM, Bernacchia A, et al. The mitochondrial production of reactive oxygen species in relation to aging and pathology. Ann N Y Acad Sci. 2004; 1011:86–100.
    1. Caprioli J. Invest Ophthalmol Vis Sci. 2013; 54: ORSF60-7.
    1. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005; 39:359–407.
    1. Saccà SC, Izzotti A. Oxidative stress and glaucoma: injury in the anterior segment of the eye. Prog Brain Res. 2008; 173:385–407.
    1. Alvarado JA, Murphy C, Juster R. Trabecular meshwork cellularity in primary open angle glaucoma and nonglaucomatous normals. Ophthalmology 1984; 91:564–579.
    1. Kahn MG, Giblin FJ, Epstein DL. Glutathione in calf trabecular meshwork and its relation to aqueous humor outflow facility. Invest Ophthalmol Vis Sci. 1983; 24:1283–1287.
    1. Zhou L, Li Y, Yue BY. Oxidative stress affects cytoskeletal structure and cell-matrix interactions in cells from an ocular tissue: the trabecular meshwork. J Cell Physiol. 1999; 180:182–189.
    1. Izzotti A, Saccà SC, Longobardi M, Cartiglia C. Sensitivity of ocular anterior chamber tissues to oxidative damage and its relevance to the pathogenesis of glaucoma. Invest Ophthalmol Vis Sci. 2009; 50:5251–5258.
    1. Izzotti A, Saccà SC, Cartiglia C, De Flora S. Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med. 2003; 114:638–646.
    1. Sacca SC, Bolognesi C, Battistella A, et al. Gene-environment interactions in ocular diseases. Mutat Res. 2009; 667:98–117.
    1. Saccà SC, Pascotto A, Camicione P, et al. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol. 2005; 123:458–463.
    1. Fernández-Durango R, Fernández-Martínez A, García-Feijoo J, et al. Expression of nitrotyrosine and oxidative consequences in the trabecular meshwork of patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2008; 49:2506–2511.
    1. Izzotti A, Longobardi M, Cartiglia C, Saccà SC. Proteome alterations in primary open angle glaucoma aqueous humor. J Proteome Res. 2010; 9:4831–4838.
    1. Sacc SC, Izzotti A. Oxidative stress in anterior segment of primary pen angle glaucoma, Glaucoma—Current Clinical and Research Aspects. Dr Gunvant Pinakin.(ed.); 2011; pp. 1–23. from:
    1. Bagnis A, Izzotti A, Centofanti M, Saccà SC. Aqueous humor oxidative stress proteomic levels in primary open angle glaucoma. Exp Eye Res. 2012; 103:55–62.
    1. Kountouras J, Mylopoulos N, Boura P, et al. Relationship between Helicobacter Pylori infection and glaucoma. Ophthalomology 2001; 108:599–604.
    1. Kontouras J, Mylopoulos N, Chatzopoulos D, et al. Eradication of Helicobacter pylori may be beneficial in the management of chronic open-angle glaucoma. Arch Intern Med 2002; 162:1237–1244.
    1. Kountouras J, Mylopoulos N, Konstas AG, et al. Increased levels of Helicobacter pylori IgG antibodies in aqueous humor of patients with primary open-angle and exfoliation glaucoma. Graefes Arch Clin Exp Ophthalmol 2003; 241:884–890.
    1. Davies GR, Simmonds NJ, Stevens TR, et al. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut 1994; 35:179–185.
    1. Zavos C, Kountouras J, Sakkias G, et al. Histological presence of Helicobacter pylori bacteria in the trabeculum and iris of patients with primary open-angle glaucoma. Ophthalmic Res. 2012; 47:150–156.
    1. Miedany Y, Baddour M, Ahmed I, Fahmy H. Sjogren's syndrome: concomitant Hp infection and possible correlation with clinical parameters. Joint Bone Spine 2005; 72:135–141.
    1. Halliwell B. Antioxidants in human health and diseases. Ann Rev Nutr 1996; 16:33–50.
    1. Correa P. The role of antioxidants in gastric carcinogenesis. Crit Rev Food Sci Nutr 1995; 53:59–64.
    1. Kountouras J, Chatzopoulos D, Zavos C. Reactive oxygen metabolites and upper gastrointestinal diseases. Hepatogastroenterology. 2001; 48:743–751.
    1. Ding SZ, Goldberg JB, Hatakeyama M. Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol. 2010; 6:851–862.
    1. Figura N, Tabaqchali S. Bacterial pathogenic factors. Curr Opin Gastroenterol 1996; 12 Suppl. 1:11–15.
    1. Galmiche A, Rassow J, Doye A, et al. The N-terminal 34 kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochrome c release. EMBO J. 2000; 19:6361–6370.
    1. Boquet P, Ricci V, Galmiche A, Gauthier NC. Gastric cell apoptosis and Hp: has the main function of VacA finally been identified? Trends Microbiol. 2003; 11:410–413.
    1. Galmiche A, Rassow J. Targeting of Helicobacter pylori VacA to mitochondria. Gut Microbes. 2010; 1:392–395.
    1. Ramos RF, Sumida GM, Stamer WD. Cyclic mechanical stress and trabecular meshwork cell contractility. Invest Ophthalmol Vis Sci. 2009; 50:3826–3832.
    1. Osman MA, Bloom GS, Tagoe EA. Helicobacter pylori-induced alteration of epithelial cell signaling and polarity: a possible mechanism of gastric carcinoma etiology and disparity. Cytoskeleton (Hoboken). 2013; 70:349–359.
    1. Etingin OR, Silverstein RL, Friedman HM, Hajjar DP. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. Cell. 1990; 61:657–662.
    1. Dechend R, Maass M, Gieffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation. 1999; 100:1369–1373.
    1. Zhu J, Quyyumi AA, Norman JE, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol. 2000; 85:140–146.
    1. Prasad A, Zhu J, Halcox JP, et al. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation. 2002; 106:184–190.
    1. Chen BF, Xu X, Deng Y, et al. Relationship between Helicobacter pylori infection and serum interleukin-18 in patients with carotid atherosclerosis. Helicobacter. 2013; 18:124–128.
    1. Bidault G, Garcia M, Vantyghem MC, et al. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2013; 33:2162–2171.
    1. Blum A, Tamir S, Mualem K, et al. Endothelial dysfunction is reversible in Helicobacter pylori-positive subjects. Am J Med. 2011; 124:1171–1174.
    1. Izzotti A, Saccà SC, Di Marco B, et al. Antioxidant activity of timolol on endothelial cells and its relevance for glaucoma course. Eye (Lond). 2008; 22:445–453.
    1. Saccà SC, Centofanti M, Izzotti A. New proteins as vascular biomarkers in primary open angle glaucomatous aqueous humor. Invest Ophthalmol Vis Sci. 2012; 53:4242–4253.
    1. Izzotti A, Saccà SC, Bagnis A, Recupero SM. Glaucoma and Helicobacter pylori infection: correlations and controversies. Br J Ophthalmol. 2009; 93:1420–1427.
    1. Kim JM, Park KH, Kim SH, et al. Investigation of the Association between Helicobacter pylori infection and normal tension glaucoma. Invest Ophthalmol Vis Sci. 2011; 52:665–668.
    1. Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmol. 2008; 86:126–145.
    1. Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol. 1996; 114:689–692.
    1. Loo RH, Scott IU, Flynn HW, Jr, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002; 22:19–24.
    1. Kitaya N, Nagaoka T, Hikichi T, et al. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 2003; 87:709–712.10.1136/bjo.87.6.709
    1. Piccolino Cardillo F, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994; 14:231–242.
    1. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine-green videoangiography of occult choroidal neovascularization. Ophthalmology. 1994; 101:1727–1735.
    1. Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996; 16:203–213.
    1. Adiloglu AK, Nazli C, Cicioglu-Aridogan B, et al. Gastroduodenal Helicobacter pylori infection diagnosed by Helicobacter pylori stool antigen is related to atherosclerosis. Acta Cardiol. 2003; 58:335–339.
    1. Gabrielli M, Santoliquido A, Cremonini F, et al. CagA-positive cytotoxic Hp strains as a link between plaque instability and atherosclerotic stroke. Eur Heart J. 2004; 25:64–68.
    1. Franceschi F, Sepulveda AR, Gasbarrini A, et al. Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation 2002; 106:430–434.
    1. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunisation. Atherosclerosis 2003; 167:177–185.
    1. Bouzas EA, Scott MH, Mastorakos G, et al. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol. 1993; 111:1229–1233.
    1. Tewari HK, Gadia R, Kumar D, et al. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthamol Vis Sci. 2006; 47:3474–3478.
    1. Yamada R, Yamada S, Ishii A, Tane S. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi. 1993; 97:955–960.
    1. Shin MC, Lim JW. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina. 2011; 31:1937–1943.
    1. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002; 47:431–448.
    1. Jones JP., Jr Intravascular coagulation and osteonecrosis. Clin Orthop. 1992; 277:41–53.
    1. Walker BR, Williams BC. Corticosteroids and vascular tone: mapping the messenger maze. Clin Sci. 1992; 82:597–605.PMID: [1320537].
    1. Caccavale A, Romanazzi F, Imparato M, et al. Central serous chorioretinopathy: a pathogenetic model. Clin Ophthalmol. 2011; 5:239–243.
    1. Nadeau S, Nguyen F, Guigou S. Serous central chorioretinopathy and tadalafil: a case report. J Fr Ophtalmol. 2012; 35:121.
    1. Moshirfar M, Hsu M, Schulman J, et al. The incidence of central serous chorioretinopathy after photorefractive keratectomy and laser in situ keratomileusis. J Ophthalmol. 2012; 2012:904215.
    1. Kloos P, Laube I, Thoelen A. Obstructive sleep apnea in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2008; 246:1225–1228.
    1. Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology. 2004; 111:244–249.
    1. Allibhai ZA, Gale JS, Sheidow TS. Central serous chorioretinopathy in a patient taking sildenafil citrate. Ophthalmic Surg Lasers Imaging. 2004; 35:165–167.
    1. Koyama M, Mizota A, Igarashi Y. Seventeen cases of central serous chorioretinopathy associated with systemic corticosteroid therapy. Ophthalmologica. 2004; 218:107–110.
    1. Carvalho-Recchia CA, Yannuzzi LA, Negrão S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002; 109:1834–1837.
    1. Costen MT, Parkin BT, Davison CR, Crick MP. Central serous chorioretinopathy and antiphospholipid antibodies-results of a pilot study. Eye (Lond). 2004; 18:938.
    1. Dorenboim Y, Rehany U, Rumelt S. Central serous chorioretinopathy associated with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2004; 242:346–349.
    1. Nucci C, Corsi A, Mancino R, Macri G. Central serous chorioretinopathy in patients with psoriasis. Acta Ophthalmol Scand. 2004; 82:105–107.
    1. Michael JC, Pak J, Pulido J, de Venecia G. Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am J Ophthalmol. 2003; 136:182–185.
    1. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003; 110:698–703.
    1. Spahn C, Wiek J, Burger T, Hansen L. Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol. 2003; 87:704–708. 10.1136/bjo.87.6.704
    1. Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986; 84:799–845.
    1. Katsimpris JM, Vandoros M, Petropoulos IK, Andrikopoulos P. Central serous chorioretinopathy associated with adrenal myelolipoma. Klin Monbl Augenheilkd. 2003; 220:199–203.
    1. Karashima K, Fujioka S, Harino S. Two cases of central serous chorioretinopathy treated with photocoagulation after bone marrow transplantation. Retina. 2002; 22:651–653.
    1. Giusti C. Central serous chorioretinopathy: a new extragastric manifestation of Helicobacter pylori? Analysis of a clinical case. Clin Ter. 2001; 152:393–397.
    1. Weenink AC, Borsje RA, Oosterhuis JA. Familial chronic central serous chorioretinopathy. Ophthalmologica. 2001; 215:183–187.
    1. Park DW, Schatz H, Gaffney MM, et al. Central serous chorioretinopathy in two families. Eur J Ophthalmol. 1998; 8:42–47.
    1. Zamir E, Chowers I. Central serous chorioretinopathy in a patient with cryoglobulinaemia. Eye (Lond). 1999; 13:265–266.
    1. Cunningham ET, Jr, Alfred PR, Irvine AR. Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology. 1996; 103:2081–2090.
    1. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol. 2013; 41:201–214.
    1. Giusti C. Association of Helicobacter pylori with central serous chorioretinopathy: hypotheses regarding pathogenesis. Medical Hypotheses. 2004; 63:524–527.
    1. Cotticelli L, Borrelli M, D’Alessio AC, et al. Central serous chorioretinopathy and Helicobacter pylori. Eur J Ophthalmol. 2006; 16:274–278.
    1. Casella AM, Berbel RF, Bressanim GL, et al. Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy. Clinics (Sao Paulo). 2012; 67:1047–1052.
    1. Oshima T, Ozono R, Yano Y, et al. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol. 2005; 45:1219–1222.
    1. Szklo M, Ding J, Tsai MY, et al. Individual pathogens, pathogen burden and markers of subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. J Cardiovasc Med (Hagerstown). 2009; 10:747–751.
    1. Coskun S, Kasirga E, Yilmaz O, et al. Is Helicobacter pylori related to endothelial dysfunction during childhood? Pediatr Int. 2008; 50:150–153.
    1. Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L, et al. The effect of Helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis. 2011; 17:99–103.
    1. Dang Y, Mu Y, Zhao M, et al. Ther Clin Risk Manag. 2013; 9:355–360.
    1. Lehmann Ch, Bac VH, Pavlovic D, et al. Metronidazole improves intestinal microcirculation in septic rats independently of bacterial burden. Clin Hemorheol Microcirc. 2006; 34:427–438.
    1. Stone AF, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation. 2002; 106:1219–1223.
    1. Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007; 31:170–184.
    1. Cahill M, Barnes C, Moriarty P, et al. Ocular adnexal lymphoma-comparison of MALT lymphoma with other histological types. Br J Ophthalmol. 1999; 83:742–747.
    1. Ferreri AJ, Dolcetti R, Du MQ, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Ann Oncol 2008; 19:835–846.
    1. Sarraf D, Jain A, Dubovy S, et al. Mucosa-associated lymphoid tissue lymphoma with intraocular involvement. Retina 2005; 25:94–98.
    1. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991; 338:1175–1176.
    1. Mobley HL, Hu LT, Foxal PA. Helicobacter pylori urease: properties and role in pathogenesis. Scand J Gastroenterol 1991; 187:39–46.
    1. Wroblewski LE, Peek RM, Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010; 23:713–739.
    1. Benktander J, Ångström J, Breimer ME, Teneberg S. Redefinition of the carbohydrate binding specificity of Helicobacter pylori BabA adhesin. J Biol Chem. 2012; 287:31712–31724.
    1. Peek RM, Jr, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol. 2006; 208:233–248.
    1. Blaser MJ, Parsonnet J. Parasitism by the “slow” bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest 1994; 94:4–8.
    1. Bodger K, Crabtree JE. Helicobacter pylori and gastric inflammation. Br Med Bull 1998; 54:139–150.
    1. Jung HC, Kim JM, Song IS, Kim CY. Helicobacter pylori induces an array of pro-inflammatory cytokines in human gastric epithelial cells: quantification of mRNA for interleukin-8-1α/β, granulocyte-macro-phage colony-stimulating factor, monocyte chemoattractant protein-1and tumour necrosis factor-α. J Gastroenterol Hepatol 1997; 12:473–480.
    1. Kranzer K, Eckhardt A, Aigner M, et al. Induction of maturation and cytokine release of human dendritic cells by Helicobacter pylori. Infect Immun 2004; 72:4416–4423.
    1. O’Keeffe J, Moran AP. Conventional, regulatory, and unconventional T cells in the immunologic response to Helicobacter pylori. Helicobacter 2008; 13:1–19.
    1. Yeh PY, Kuo SH, Yeh KH, et al. A pathway for tumor necrosis factor-α-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-κB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus. J Biol Chem. 2006; 281:167–175.
    1. Suzuki T, Kato K, Ohara S, et al. Localization of antigen-presenting cells in Helicobacter pylori-infected gastric mucosa. Pathol Int 2002; 52:265–271.
    1. Necchi V, Candusso ME, Tava F, et al. Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori. Gastroenterology 2007; 132:1009–1023.
    1. Borlace GN, Butler RN, Brooks DA. Monocyte and macrophage killing of Helicobacter pylori: relationship to bacterial virulence factors. Helicobacter 2008; 13:380–387.
    1. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291:187–194.
    1. Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993; 34:571–574.
    1. Bergman MP, D’Elios MM Cytotoxic T cells in Hp-related gastric autoimmunity and gastric lymphoma. J Biomed Biotechnol. 2010; 2010:104918.
    1. Hussell T, Isaacson PG, Crabtree JE, Spencer JO. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol. 1996; 178:122–127.
    1. Munari F, Lonardi S, Cassatella MA, et al. Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood. 2011; 117:6612–6616.
    1. Witkowska M, Smolewski P. Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma. Mediators Inflamm. 2013; 2013:523170.
    1. D’Elios MM, Amedei A, Manghetti M, et al. Impaired T-cell regulation of B-cell growth in Helicobacter pylori-related gastric low-grade MALT lymphoma. Gastroenterology. 1999; 117:1105–1112.
    1. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004; 4:644–653.
    1. Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006; 107:3034–3044.
    1. Zinzani PL. The many faces of marginal zone lymphoma. Hematology Am Soc Hematol Educ Program. 2012; 2012:426–432.
    1. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood. 1997; 90:766–775.
    1. Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987; 103:234–235.
    1. Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin. 2005; 45:1–13.
    1. Barisani-Asenbauer T, Maca SM, Mejdoubi L, et al. Uveitis—a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patients. Orphanet J Rare Dis. 2012; 7:57.
    1. Otasevic L, Zlatanovic G, Stanojevic-Paovic A, et al. Helicobacter pylori: an underestimated factor in acute anterior uveitis and spondyloarthropathies? Ophthalmologica. 2007; 221:6–13.
    1. Kim JM, Park KH, Choi MJ, et al. Eye (Lond). 2012; 26:1503–1509.
    1. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol. 2002; 14:337–341.10.1097/01.BOR.0000017926.78715.FD
    1. Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha-2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol. 2008; 146:837–844.
    1. Orchard TR, Chua CN, Ahmad T, et al. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology. 2002; 123:714–718.
    1. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature. 1980; 286:611–613. 10.1038/286611a0
    1. Yadav UC, Kalariya NM, Ramana KV. Emerging role of antioxidants in the protection of uveitis complications. Curr Med Chem. 2011; 18:931–942.
    1. Nagata M. Inflammatory cells and oxygen radicals. Curr Drug Targets Inflamm Allergy. 2005; 4:503–504.
    1. Srivastava SK, Ramana KV. Focus on molecules: nuclear factor-kappaB. Exp Eye Res. 2009; 88:2–3.
    1. Han D, Ybanez MD, Ahmadi S, et al. Redox regulation of tumor necrosis factor signaling. Antioxid Redox Signal. 2009; 11:2245–2263.
    1. Gloire G, Piette J. Redox regulation of nuclear post-translational modifications during NF-kappaB activation. Antioxid Redox Signal. 2009; 11:2209–2222.
    1. Oliveira-Marques V, Marinho HS, Cyrne L, Antunes F. Role of hydrogen peroxide in NF-kappaB activation: from inducer to modulator. Antioxid Redox Signal. 2009; 11:2223–2243.
    1. Trouba KJ, Hamadeh HK, Amin RP, Germolec DR. Oxidative stress and its role in skin disease. Antioxid Redox Signal 2002; 4:665–673.
    1. Harris PR, Mobley HLT, Perez-Perez GI, et al. Helicobacter pylori urease is a potent stimulus of mononuclear phagocyte activation and imflammatory cytokine production. Gastroenterology 1996; 11:419–425.
    1. Verma MJ, Lloyd A, Rager H, et al. Chemokines in acute anterior uveitis. Curr Eye Res 1997; 16:1202–1208.PMID: [9426952].
    1. Appelmelk BJ, Simoons-Smit I, Negrini R, et al. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect Immun 1996; 64:2031–2040.
    1. Otasevic L, Walduck A, Meyer TF, et al. Helicobacter pylori infection in anterior uveitis. Infection. 2005; 33:82–85.PMID: [15827876].
    1. DeLano FA, Balete R, Schmid-Schonbein GW. Control of oxidative stress in microcirculation of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2005; 288:H805–H812.
    1. Halliday GM. Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat Res. 2005; 571:107–120.
    1. Sun YQ, Girgensone I, Leanderson P, et al. Effects of antioxidant vitamin supplements on Helicobacter pylori-induced gastritis in Mongolian gerbils. Helicobacter. 2005; 10:33–42.
    1. Calvino Fernández M, Parra Cid TH. pylori and mitochondrial changes in epithelial cells The role of oxidative stress. Rev Esp Enferm Dig. 2010; 102:41–50.
    1. May JM. Is ascorbic acid an antioxidant for the plasma membrane? FASEB J. 1995; 13,:1999e1006.
    1. Xu P, Lin Y, Porter K, Liton PB. Ascorbic acid modulation of iron homeostasis and lysosomal function in trabecular meshwork cells. J Ocul Pharmacol Ther. 2014; 30:246–253.
    1. Aditi A, Graham DY. Vitamin C, gastritis, and gastric disease: a historical review and update. Dig Dis Sci. 2012; 57:2504–2515.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi